Femme et Homme | 18 ans et plus
- | Pays :
- France
- | Organes :
- Tête et cou
- | Spécialités :
- Thérapies Ciblées
Extrait
An open-label, international, multi-center, phase I/II, dose-escalation trial investigating the safety of zalutumumab, a human monoclonal epidermal growth factor receptor antibody in combination with radiotherapy, in patients with stage III, IVa or IVb locally advanced squamous cell carcinoma of the head and neck ineligible for platinum based chemotherapy.
Extrait Scientifique
en cours d'intégration;